The B.1.1.529/Omicron variant of SARS-CoV-2 was only recently detected in southern Africa,
but its subsequent spread has been extensive, both regionally and globally 1 . It is …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …

SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have surged notably to become
dominant in the United States and South Africa, respectively 1 , 2 . These new subvariants …

Background Hydroxychloroquine has been widely administered to patients with Covid-19
without robust evidence supporting its use. Methods We examined the association between …

Objective To characterize patients with coronavirus disease 2019 (covid-19) in a large New
York City medical center and describe their clinical course across the emergency department…

HIV-1 has evolved multiple mechanisms to elude immune control. The view of virus as
classifiable into distinct subtypes needs to reflect the reality of the constant emergence of new …

Background A safe and effective vaccine for the prevention of human immunodeficiency
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime–…

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …

Background and Aims Coronavirus disease 2019 (COVID‐19) has been associated with acute
liver injury (ALI) manifested by increased liver enzymes in reports worldwide. Prevalence …